Blog

Latest news about encapsia

DIA 2019 - There's nothing quite like Encapsia

What a week in San Diego at DIA 2019! After arriving home late (or early Friday morning) and exhausted from the long journey, I still have an energy coursing through my veins fuelled by the week we left behind. As I reflect what the week meant for us, I feel an excitement about the future of both Encapsia and our industry.

Having observed the conference themes and the offerings from other vendors, I can’t help but feel there is nothing quite like Encapsia. It is not only built for today’s trials, but also for tomorrow’s. One of the themes of the week was the exciting area of artificial intelligence. Encapsia leads the market with analytics capabilities that are already proven to support AI, by analyzing and populating data from CT scans directly into the CRF.

Themes from DIA in previous years, in my opinion, have never fully reached fruition. Have we completely implemented risk based monitoring? There has been some great work in the area, but EDC systems are typically not flexible enough to dynamically adjust SDV down to the datapoint level. Encapsia has no hard-wired SDV mode, but instead has fully configurable review modes that allow you to dynamically set and adjust what requires SDV or any other type of review!

Overall, I am hugely encouraged by what we have seen at DIA 2019. Firstly, the industry is heading in the right direction, and secondly, Encapsia is made for that direction. There really isn’t anything quite like Encapsia for the future of clinical trials.

DIA 2019 - There's nothing quite like Encapsia

Latest articles

It is no secret that there is a digital transformation happening across life sciences and healthcare. This seismic shift is being facilitated by cutting-edge technology that is enabling the interrogation and aggregation of the vast quantities of data that we now have at our fingertips. The adoption of automated processes using technologies like artificial intelligence (AI), which incorporates human intelligence into machines through a set of rules, and machine learning (ML), an application of AI whereby the computer learns automatically through its experiences, is key to collecting and analyzing the vast and varied data that is now available and facilitating a move to a personalized approach to medicine.
As the ways in which clinical trials are conducted and monitored continue to modernize at pace, there is an urgent need for digital transformation in the industry. If sponsors are to realize their goals of running flexible, decentralized trials (DCT), risk-based management (RBM), or adaptive trials while adopting big data, artificial intelligence / machine learning (AI/ML), the emphasis must now be on technology solutions that optimize clinical trial data workflows by bringing the technology to the data.
Innovative technology for clinical trials is now, more than ever, necessary to deliver decentralized trials (DCT) and enable design of hybrid protocols that support trial continuity and patient-centricity. We’ve added new capabilities for encapsia, after we’ve seen increased demand for its use in decentralized trials. Encapsia delivers a complete solution to gather and manage multiple live clinical data sources and apply real-time data management, sophisticated visualizations, analytics, and AI. Encapsia was designed to address the pain around remote collection, integration, and availability of disparate data.